Moderna (MRNA) PT Raised to $35 at Needham & Company, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $221.72 -0.47%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Needham & Company analyst Alan Carr raised the price target on Moderna (NASDAQ: MRNA) to $35.00 (from $28.00) while maintaining a Hold rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Moderna (MRNA) to Market Perform
- Twilio (TWLO) PT Lowered to $240 at Needham
- Glaukos Corporation (GKOS) PT Raised to $251 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & Company, Earnings, Alan CarrSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
